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Background
Theravectys develops a new generation of prophylactic
and therapeutic vaccines using optimized lentiviral vec-
tors. It’s most advanced product, a therapeutic anti-HIV
vaccinal treatment, will enter clinical Phase I/II within a
few weeks. This vaccination will allow seropositive
patients to gain an immunological status identical to the
so-called “Functional Cured” patients who develop an
efficient immunological response capable of controlling
the infection without therapy.
Methods
Vaccine candidates are integrative and self-inactivated
live-recombinant lentiviral vectors. They encode an HIV
antigen, under the regulation of a patented promoter that
is preferentially induced in APC (generating of a strong,
specific and long lasting T-cell immune response), and
showing a basal level expression in all cells (allowing their
elimination by the settled immune response).
Furthermore, Theravectys developed a vaccination regi-
men based on iterative immunizations with lentivectors
encoding the same HIV transgene, relying on different
VSV-G serotypes for pseudotyping without generating
cross-neutralizing antibodies. These candidates were clas-
sified as “Live recombinant vectored vaccines” (EMA,
2011).
Results
Theravectys set up an innovative manufacturing process
combining high production yields, impurity profiles
compatible with direct injections into humans and high
immunogenicity.
Pilot and GMP batches have been manufactured and
GLP preclinical studies (amongst which biodistribution,
shedding and toxicity) performed, that showed the
restricted diffusion of the vaccine candidates after injection
and their fast disappearance within few weeks, correlated
with an absence of macroscopic and microscopic toxicity.
Conclusion
These data allowed the settlement of an anti-HIV thera-
peutic Phase I/II clinical trial that should receive the
authorization of the French regulatory agency before the
end of July.
This trial will be held in France and Belgium and plans
the enrollment of 36 HIV-1 infected patients. Thera-
vectys’ anti-HIV vaccine treatment will be assessed at
three doses and safety, tolerability and immunogenicity
compared to a placebo group. Results are expected by
September 2014 with intermediary analyses in September
2013.
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